Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. Our medicines are helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience, fibrosis and others. We have built a sustainable pipeline of potential therapies, and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient at the right time to achieve the best outcome.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

UPSTART BLADE NABS BRISTOL-MYERS SQUIBB RESEARCH EXECUTIVE AS NEW R&D LEAD

fiercebiotech | August 21, 2017

news image

Blade Therapeutics is looking to sharpen its focus after hiring Bristol-Myers Squibb’s former fibrosis research lead as its new EVP of research. The biotech, which is working on antifibrotic (scarring) therapies, has appointed Maria E. Fuentes, Ph.D., to lead its antifibrotic programs in preclinical testing. Blade’s flagship program, focused on a small molecule cysteine protease inhibitor, is expected to enter IND-enabling studies by year-end 2017. Fuentes comes to the small, private...

Read More

FDA ACTION ALERT: REGENERON, BRISTOL-MYERS SQUIBB AND INCYTE

Biospace | May 13, 2019

news image

May has been a fairly slow month for approvals by the U.S. Food and Drug Administration (FDA). There are currently only two scheduled for the rest of the month, with a third that has been withdrawn. Let’s take a look. Regeneron’s Eylea for Diabetic Retinopathy Regeneron Pharmaceuticals has a target action date of May 13 for its supplemental Biologics License Application (sBLA) of Eylea (aflibercept) injection for diabetic retinopathy (DR). DR is the leading cause of vision loss in di...

Read More

STEM CELL MODELS OF HUMAN SPINE DEVELOPMENT UNVEILED

Drug Target Review | January 15, 2020

news image

Scientists have created the first lab-dish models of the cellular clock, where each ‘tick’ stimulates the formation of the vertebra, which uses stem cells derived from adult human tissue. Over 20 years ago, Olivier Pourquié’s lab at Harvard University, US discovered a cellular clock in chicken embryos where each ‘tick’ stimulates the formation of a structure called a somite that ultimately becomes a vertebra. Now, Pourquié has led one of two teams to c...

Read More

BLUEBIRD BIO LAUNCHES FIRST GENE THERAPY FOR BETA THALASSEMIA IN GERMANY

Labiotech | January 15, 2020

news image

The US company bluebird bio has launched the first gene therapy for the blood disorder transfusion-dependent beta thalassemia in the EU, with a hospital in Germany becoming its first qualified treatment center. Bluebird bio’s gene therapy, branded as Zynteglo, was given conditional market approval by the EU in June 2019. It was the first gene therapy approved to treat people over 12 years of age with all but the most severe form of transfusion-dependent beta thalassemia, a condition that n...

Read More
news image

UPSTART BLADE NABS BRISTOL-MYERS SQUIBB RESEARCH EXECUTIVE AS NEW R&D LEAD

fiercebiotech | August 21, 2017

Blade Therapeutics is looking to sharpen its focus after hiring Bristol-Myers Squibb’s former fibrosis research lead as its new EVP of research. The biotech, which is working on antifibrotic (scarring) therapies, has appointed Maria E. Fuentes, Ph.D., to lead its antifibrotic programs in preclinical testing. Blade’s flagship program, focused on a small molecule cysteine protease inhibitor, is expected to enter IND-enabling studies by year-end 2017. Fuentes comes to the small, private...

Read More
news image

FDA ACTION ALERT: REGENERON, BRISTOL-MYERS SQUIBB AND INCYTE

Biospace | May 13, 2019

May has been a fairly slow month for approvals by the U.S. Food and Drug Administration (FDA). There are currently only two scheduled for the rest of the month, with a third that has been withdrawn. Let’s take a look. Regeneron’s Eylea for Diabetic Retinopathy Regeneron Pharmaceuticals has a target action date of May 13 for its supplemental Biologics License Application (sBLA) of Eylea (aflibercept) injection for diabetic retinopathy (DR). DR is the leading cause of vision loss in di...

Read More
news image

STEM CELL MODELS OF HUMAN SPINE DEVELOPMENT UNVEILED

Drug Target Review | January 15, 2020

Scientists have created the first lab-dish models of the cellular clock, where each ‘tick’ stimulates the formation of the vertebra, which uses stem cells derived from adult human tissue. Over 20 years ago, Olivier Pourquié’s lab at Harvard University, US discovered a cellular clock in chicken embryos where each ‘tick’ stimulates the formation of a structure called a somite that ultimately becomes a vertebra. Now, Pourquié has led one of two teams to c...

Read More
news image

BLUEBIRD BIO LAUNCHES FIRST GENE THERAPY FOR BETA THALASSEMIA IN GERMANY

Labiotech | January 15, 2020

The US company bluebird bio has launched the first gene therapy for the blood disorder transfusion-dependent beta thalassemia in the EU, with a hospital in Germany becoming its first qualified treatment center. Bluebird bio’s gene therapy, branded as Zynteglo, was given conditional market approval by the EU in June 2019. It was the first gene therapy approved to treat people over 12 years of age with all but the most severe form of transfusion-dependent beta thalassemia, a condition that n...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us